Factor VIII products and inhibitor development in severe hemophilia A

New England Journal of Medicine

Volumn 368, Issue 3, 2013, Pages 231-239

  Gouw, Samantha C ^a,b   Van Der Bom, Johanna G ^c,d   Ljung, Rolf ^e   Escuriola, Carmen ^f   Cid, Ana R ^g   Claeyssens Donadel, Ségolène ^h   Van Geet, Christel ^i,j   Kenet, Gili ^k   Mäkipernaa, Anne ^l   Molinari, Angelo Claudio ^m   Muntean, Wolfgang ^o   Kobelt, Rainer ^p   Rivard, George ^q   Santagostino, Elena ⁿ   Thomas, Angela ^r   Van Den Berg, H Marijke ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Center for Clinical Transfusion Research   (Netherlands)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h TOULOUSE UNIVERSITY HOSPITAL   (France)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k MINISTRY OF HEALTH   (Israel)

^l UNIVERSITY OF HELSINKI   (Finland)

^m G GASLINI INSTITUTE   (Italy)

ⁿ FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^o Universitatsklinik fur Kinder und Jugendheilkunde Graz   (Austria)

^p UNIVERSITY OF BERN   (Switzerland)

^q UNIVERSITY OF MONTREAL   (Canada)

^r ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ANTIBODY TITER; ARTICLE; BLOOD LEVEL; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG RESPONSE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SENSITIVITY ANALYSIS;

EID: 84872450786     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1208024     Document Type: Article

References (34)

1. Berntorp E, Boulyjenkov V, Brettler D, et al. Modern treatment of haemophilia. Bull World Health Organ 1995;73:691-701.
2. Schwaab R, Brackmann HH, Meyer C, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 1995;74:1402-6.
3. Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012;119:2922-34.
4. Astermark J, Berntorp E, White GC, Kroner BL. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia 2001;7:267-72.
5. Aledort LM, Dimichele DM. Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia 1998;4:68.
6. Hay CR, Ollier W, Pepper L, et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. Thromb Haemost 1997;77:234-7.
7. Oldenburg J, Picard JK, Schwaab R, et al. HLA genotype of patients with severe haemophilia A due to intron 22 inversion with and without inhibitors of factor VIII. Thromb Haemost 1997;77:238-42.
8. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006;107:3167-72.
9. Astermark J, Oldenburg J, Carlson J, et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006;108:3739-45.
10. Astermark J, Wang X, Oldenburg J, Berntorp E, Lefvert AK. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007;5:263-5.
11. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia 2011;17:641-9.
12. Pavlova A, Delev D, Lacroix-Desmazes S, et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009;7:2006-15.
13. Bafunno V, Santacroce R, Chetta M, et al. Polymorphisms in genes involved in autoimmune disease and the risk of FVIII inhibitor development in Italian patients with haemophilia A. Haemophilia 2010;16:469-73.
14. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648-54.
15. Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007;5:1383-90.
16. Kurnik K, Bidlingmaier C, Engl W, et al. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010;16:256-62.
17. Maclean PS, Richards M, Williams M, et al. Treatment related factors and inhibitor development in children with severe haemophilia A. Haemophilia 2011;17:282-7.
18. Santagostino E, Mancuso ME, Rocino A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005;130:422-7.
19. Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006;107:46-51.
20. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007;109:4693-7.
21. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003;9:418-35.
22. Iorio A, Halimeh S, Holzhauer S, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010;8:1256-65.
23. Franchini M, Tagliaferri A, Mengoli C, Cruciani M. Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: a critical systematic review. Crit Rev Oncol Hematol 2012;81:82-93.
24. Scharrer I, Ehrlich HJ. Reported inhibitor incidence in FVIII PUP studies: comparing apples with oranges? Haemophilia 2004;10:197-8.
25. Kreuz W, Gill JC, Rothschild C, et al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation. Thromb Haemost 2005;93:457-67.
26. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (Survey of Inhibitors in Plasma-Product Exposed Toddlers). Haemophilia 2007;13: Suppl 5:65-8.
27. Hay CR, Palmer B, Chalmers E, et al. The incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011;117:6367-70.
28. White GC II, Rosendaal F, Aledort LM, et al. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
29. Lee ML, Gomperts ED, Kingdon HS. A note on the calculation of recovery for factor VIII infusions. Thromb Haemost 1993;69:87.
30. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ. Factor VIII and von Willebrand factor. Thromb Haemost 1998;79:456-65.
31. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med 1990; 9:1501-15.
32. Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia 2006;12:Suppl 6:102-6.
33. Mancuso ME, Mannucci PM, Rocino A, Garagiola I, Tagliaferri A, Santagostino E. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012;10:781-90.
34. Giangrande PL. Safety and efficacy of KOGENATE(R) Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). Haemophilia 2002;8:Suppl 2:19-22.